Moderna and Merck Reveal Vaccine's Impact on Patient Survival in Deadly Skin Cancer
Monday, 3 June 2024, 13:00
Moderna and Merck Study Results
According to the latest study conducted by Moderna and Merck, the cancer vaccine, when combined with Keytruda, has shown a remarkable impact on patient survival rates in deadly skin cancer cases.
Positive Outcome and Improved Treatment
- Significant Improvement: Nearly 75% of patients remained free of cancer signs or symptoms at the 2½-year mark.
- Enhanced Therapeutic Potential: The study highlights the promising role of these treatments in extending patient survival and reducing the risk of cancer recurrence.
The joint effort by Moderna and Merck signifies a positive breakthrough in cancer vaccine research and treatment options.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.